227 related articles for article (PubMed ID: 9846890)
1. The pathogenesis and consequences of AGE formation in uraemia and its treatment.
Dawnay A; Millar DJ
Cell Mol Biol (Noisy-le-grand); 1998 Nov; 44(7):1081-94. PubMed ID: 9846890
[TBL] [Abstract][Full Text] [Related]
2. Advanced glycation endproducts (AGEs) as uremic toxins.
Schwenger V; Zeier M; Henle T; Ritz E
Nahrung; 2001 Jun; 45(3):172-6. PubMed ID: 11455783
[TBL] [Abstract][Full Text] [Related]
3. Advanced glycation end products in renal failure.
Thornalley PJ
J Ren Nutr; 2006 Jul; 16(3):178-84. PubMed ID: 16825015
[TBL] [Abstract][Full Text] [Related]
4. Accumulation of advanced glycation end products and chronic complications in ESRD treated by dialysis.
Meerwaldt R; Zeebregts CJ; Navis G; Hillebrands JL; Lefrandt JD; Smit AJ
Am J Kidney Dis; 2009 Jan; 53(1):138-50. PubMed ID: 19036487
[TBL] [Abstract][Full Text] [Related]
5. Advanced glycation end products in clinical nephrology.
Kalousová M; Zima T; Tesar V; Stípek S; Sulková S
Kidney Blood Press Res; 2004; 27(1):18-28. PubMed ID: 14679311
[TBL] [Abstract][Full Text] [Related]
6. Immunopathological changes in a uraemic rat model for peritoneal dialysis.
Zareie M; De Vriese AS; Hekking LH; ter Wee PM; Schalkwijk CG; Driesprong BA; Schadee-Eestermans IL; Beelen RH; Lameire N; van den Born J
Nephrol Dial Transplant; 2005 Jul; 20(7):1350-61. PubMed ID: 15840671
[TBL] [Abstract][Full Text] [Related]
7. Myofibroblast transdifferentiation of mesothelial cells is mediated by RAGE and contributes to peritoneal fibrosis in uraemia.
De Vriese AS; Tilton RG; Mortier S; Lameire NH
Nephrol Dial Transplant; 2006 Sep; 21(9):2549-55. PubMed ID: 16757496
[TBL] [Abstract][Full Text] [Related]
8. Oxidative stress parameters in hemodialysis patients with or without diabetes.
Atanasiu V; Stoian I; Căpuşă C; Mircescu G; Mărăcine M; Lupescu O; Vîrgolici B; Muscurel C; Manolescu B
Rom J Intern Med; 2006; 44(4):433-42. PubMed ID: 18386620
[TBL] [Abstract][Full Text] [Related]
9. Profound mishandling of protein glycation degradation products in uremia and dialysis.
Agalou S; Ahmed N; Babaei-Jadidi R; Dawnay A; Thornalley PJ
J Am Soc Nephrol; 2005 May; 16(5):1471-85. PubMed ID: 15800128
[TBL] [Abstract][Full Text] [Related]
10. Enhanced plasma levels of advanced glycation end products (AGE) and pro-inflammatory cytokines in children/adolescents with chronic renal insufficiency and after renal replacement therapy by dialysis and transplantation--are they inter-related?
Sebeková K; Podracká L; Heidland A; Schinzel R
Clin Nephrol; 2001 Dec; 56(6):S21-6. PubMed ID: 11770807
[TBL] [Abstract][Full Text] [Related]
11. Reactive glycosylation endproducts in diabetic uraemia and treatment of renal failure.
Makita Z; Bucala R; Rayfield EJ; Friedman EA; Kaufman AM; Korbet SM; Barth RH; Winston JA; Fuh H; Manogue KR
Lancet; 1994 Jun; 343(8912):1519-22. PubMed ID: 7911868
[TBL] [Abstract][Full Text] [Related]
12. Reactive carbonyl compounds related uremic toxicity ("carbonyl stress").
Miyata T; Sugiyama S; Saito A; Kurokawa K
Kidney Int Suppl; 2001 Feb; 78():S25-31. PubMed ID: 11168978
[TBL] [Abstract][Full Text] [Related]
13. Are biocompatible membranes superior for hemodialysis therapy?
van Ypersele de Strihou C
Kidney Int Suppl; 1997 Nov; 62():S101-4. PubMed ID: 9350694
[No Abstract] [Full Text] [Related]
14. Plasma levels of advanced glycation end products in children with renal disease.
Sebeková K; Podracká L; Blazícek P; Syrová D; Heidland A; Schinzel R
Pediatr Nephrol; 2001 Dec; 16(12):1105-12. PubMed ID: 11793110
[TBL] [Abstract][Full Text] [Related]
15. Nepsilon-(carboxymethyl)lysine, Nepsilon-(carboxyethyl)lysine and vascular cell adhesion molecule-1 (VCAM-1) in relation to peritoneal glucose prescription and residual renal function; a study in peritoneal dialysis patients.
van de Kerkhof J; Schalkwijk CG; Konings CJ; Cheriex EC; van der Sande FM; Scheffer PG; ter Wee PM; Leunissen KM; Kooman JP
Nephrol Dial Transplant; 2004 Apr; 19(4):910-6. PubMed ID: 15031349
[TBL] [Abstract][Full Text] [Related]
16. Oxidatively-modified and glycated proteins as candidate pro-inflammatory toxins in uremia and dialysis patients.
Piroddi M; Depunzio I; Calabrese V; Mancuso C; Aisa CM; Binaglia L; Minelli A; Butterfield AD; Galli F
Amino Acids; 2007; 32(4):573-92. PubMed ID: 17356806
[TBL] [Abstract][Full Text] [Related]
17. Low-molecular but not high-molecular advanced glycation end products (AGEs) are removed by high-flux dialysis.
Gerdemann A; Lemke HD; Nothdurft A; Heidland A; Münch G; Bahner U; Schinzel R
Clin Nephrol; 2000 Oct; 54(4):276-83. PubMed ID: 11076103
[TBL] [Abstract][Full Text] [Related]
18. Significance of proximal tubular metabolism of advanced glycation end products in kidney diseases.
Saito A; Takeda T; Sato K; Hama H; Tanuma A; Kaseda R; Suzuki Y; Gejyo F
Ann N Y Acad Sci; 2005 Jun; 1043():637-43. PubMed ID: 16037287
[TBL] [Abstract][Full Text] [Related]
19. Accumulation of advanced glycation end products, measured as skin autofluorescence, in renal disease.
Hartog JW; de Vries AP; Lutgers HL; Meerwaldt R; Huisman RM; van Son WJ; de Jong PE; Smit AJ
Ann N Y Acad Sci; 2005 Jun; 1043():299-307. PubMed ID: 16037252
[TBL] [Abstract][Full Text] [Related]
20. Cardiovascular disease in haemodialysis and peritoneal dialysis: arguments pro peritoneal dialysis.
Van Biesen W; Verbeke F; Vanholder R
Nephrol Dial Transplant; 2007 Jan; 22(1):53-8. PubMed ID: 17050633
[No Abstract] [Full Text] [Related]
[Next] [New Search]
